(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 November 2009 (05.11.2009)

PCT

(10) International Publication Number
WO 2009/134805 A3

(51) International Patent Classification:
C07K 16/22 (2006.01) *C12P 21/08* (2006.01)

(21) International Application Number:
PCT/US2009/041981

(22) International Filing Date:
28 April 2009 (28.04.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/048,522 28 April 2008 (28.04.2008) US

(71) Applicant *(for all designated States except US)*: **KALOBIOS PHARMACEUTICALS, INC.** [US/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BEBBINGTON, Christopher, R.** [GB/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US). **LUEHRSEN, Kenneth** [US/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US). **YARRANTON, Geoffrey, T.** [GB/US]; 260 East Grand Avenue, South San Francisco, CA 94080 (US).

(74) Agents: **LOCKYER, Jean, M.** et al.; Townsend And Townsend And Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
3 June 2010

(54) Title: ANTIBODIES TO GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR

FIGURE 1



Fab	Vh	Vk	Dissociation rate for binding to GM-CSF determined by surface plasmon resonance analysis (s^{-1})
FB42-8	#2	#3	1.36×10^{-4}
FB44-5	#1	#3	8.0×10^{-5}
FB77-2	#3	#1	5.57×10^{-5}
FB92-1	#4	#4	3.84×10^{-5}
FB94-1	#4	#2	3.12×10^{-5}
FB104-1	#5	#1	3.57×10^{-5}
FB106-1	#5	#2	5.4×10^{-5}

(57) Abstract: The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

WO 2009/134805 A3